Trevi Therapeutics prices $150 million stock offering at $13.00 per share
Trevi Therapeutics agreed to sell 11.6 million new common shares at $13.00 each, for about $150 million before fees, with the Company estimating net proceeds of about $141.1 million. The Company said it had about $171.8 million in cash and securities as of March 31, 2026, and that this cash plus the offering proceeds will fund operations through 2029, while the sale also adds new shares outstanding for existing holders.
Key points
- Offering of 11.6 million shares at $13.00 per share, with underwriters at $12.22 per share; closing expected on or about April 20, 2026.
- Estimated net proceeds of about $141.1 million, or about $162.4 million if the 1,740,000-share underwriter option is exercised in full.
- Cash, cash equivalents and marketable securities of about $171.8 million as of March 31, 2026, preliminary and unreviewed by the auditor.
- Company expects cash to fund operations through 2029; first Phase 3 trial topline results expected in the first half of 2028.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 17, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.